



Dr. med. Dieter Köberle

Kontakt

Dr. med. Dieter Köberle

Bereiche

Medizinische Onkologie und Hämatologie

Publikationen (48)

Burmeister K, Tornillo L, Piscuoglio S, Ng C, Köberle D, Lehmann F, Moosmann P, Horber D, Jochum W, Grobholz R, Perrina V, Matter M, Eppenberger-Castori S, Andreozzi M, Quagliata L, Terracciano L. Vascular endothelial growth factor A amplification in colorectal cancer is associated with reduced M1 and M2 macrophages and diminished PD-1-expressing lymphocytes. *PLoS one* 2017; 12:e0175563.

Rigger J, Kleger G, Semela D, Doenecke C, Rodriguez R, Meyenberger C, Köberle D, Sawatzki M. [Malignant hypoglycaemia]. *Praxis (Bern 1994)* 2014; 103:399-403.

Rigger J, Kleger G, Semela D, Doenecke C, Rodriguez R, Meyenberger C, Köberle D, Sawatzki M. Maligne Hypoglykämie. *Praxis* 2014; 103 (7):399-403.

Warschkow R, Gueller U, Köberle D, Mueller S, Steffen T, Thurnheer M, Schmied B, Tarantino I. Perioperative Blood Transfusions Do Not Impact Overall and Disease-Free Survival After Curative Rectal Cancer Resection: A Propensity Score Analysis. *Ann Surg* 2013; 259:131-138.

Helbling D, Bougel S, Leibundgut E, Benhattar J, Yan P, Baertschi D, Borner M, Widmer L, Saletti P, Rauch D, Madlung A, Winterhalder R, Burkhard R, Gloor B, Bosman F, Sun H, Gautschi O, Bodoky G, Köberle D. Neoadjuvant chemoradiotherapy with or without panitumumab in patients with wild-type KRAS, locally advanced rectal cancer (LARC): a randomized, multicenter, phase II trial SAKK 41/07. *Ann Oncol* 2012; 24:718-25.

Blum D, Köberle D, Ribi K, Hsu Schmitz S, Uitger U, Klingbiel D, Strasser F. Electronic monitoring of symptoms and syndromes associated with cancer: methods of a randomized controlled trial SAKK 95/06 E-MOSAIC. *BMC Palliat Care* 2012; 11:19.

Tarantino I, Cerny T, Steffen T, Mueller S, Schmied B, Köberle D, Merati-Kashani K, Worni M, Warschkow R, Gueller U. Elevated preoperative CEA is associated with worse survival in stage I-III rectal cancer patients. *Br J Cancer* 2012; 107:266-74.

Warschkow R, Gueller U, Köberle D, Müller S, Steffen T, Thurnherr M, Schmied B, Tarantino I. Peri-operative blood transfusions do not impact overall and disease-free survival after curative rectal cancer resection. A propensity score analysis. *Annals of surgery* 2012

Saletti P, Sessa C, De Dosso S, Cerny T, Renggli V, Köberle D. Phase I dose-finding study of vandetanib in combination with gemcitabine in locally advanced unresectable or metastatic pancreatic adenocarcinoma. *Oncology* 2011; 81:50-4.

Baumann M, Cerny T, Sommacal A, Köberle D. Langerhans cell histiocytosis with central nervous system involvement-complete response to 2-chlorodeoxyadenosine after failure of tyrosine kinase inhibitor therapies with sorafenib and imatinib. *Hematol Oncol* 2011

Köberle D, Thürlimann B, Pilop C, Crowe S, Öhschlegel C, von Moos R, Zaman K, Pagani O, Jost L, Ruhstaller T, Swiss Group for Clinical Cancer Research (SAKK). Combination of trastuzumab and letrozole after resistance to sequential trastuzumab and aromatase inhibitor monotherapies in patients with estrogen receptor-positive, HER-2-positive advanced breast cancer: a proof-of-concept trial (SAKK 23/03). *Endocr Relat Cancer* 2011; 18:257-64.

Köberle D, Samaras P. Recent advances and future challenges in the treatment of hepatocellular and biliary tract carcinomas. *Memo* 4 2011; 4:94-97.

Jörger M, Templeton A, Köberle D, Engler H, Riesen W, Thürlimann B. Procollagen type I N-propeptide is a predictor of skeletal morbidity in patients with malignant osteolytic bone disease on bisphosphonates. *Cancer Chemother Pharmacol* 2010

Ruhstaller T, Köberle D, von Briel C, Lombriser N, Lohri A, Pederiva S, von Moos R, Thierstein S, Borner M, Schuller J, Ribi K, Templeton A, Popescu R. Intense therapy in patients with locally advanced esophageal cancer beyond hope for surgical cure: a prospective, multicenter phase II trial of the Swiss Group for Clinical Cancer Research (SAKK 76/02). *Onkologie* 2010; 33:222-8.

von Moos R, Lanz D, Simcock M, Köberle D, Cathomas R, Uhlmann C, Widmer L, Ruhstaller T, Roth A, Popescu R. Oxaliplatin, irinotecan and capecitabine (OCX) for first-line treatment of advanced/metastatic colorectal cancer: a phase I trial (SAKK 41/03). *Onkologie* 2010; 33:295-9.

Ruhstaller T, Köberle D, von Briel C, Lombriser N, Lohri A, Pederiva S, von Moos R, Thierstein S, Borner M, Schuller J, Ribi K, Templeton A, Popescu R. Intense therapy in patients with locally advanced esophageal cancer beyond hope for surgical cure: a prospective, multicenter phase II trial of the Swiss Group for Clinical Cancer. *Onkologie* 2010; 33:222-228.

Klaeser B, Ruhstaller T, von Moos R, Albrecht S, Caspar C, Pestalozzi B, Zünd M, Brauchli P, Cescato-Wenger C, Hany T, Balmer-Majno S, Widmer L, Köberle D, Schuller J, Nitzsche E, Lange J. Limited predictive value of FDG-PET for response assessment in the preoperative treatment of esophageal cancer: results of a prospective multi-center trial (SAKK 75/02). *Onkologie* 2009; 32:724-30.

Cathomas R, Köberle D, Ruhstaller T, Mayer G, Räss A, Mey U, von Moos R. Heated (37 degrees C) oxaliplatin infusion in combination with capecitabine for metastatic colorectal carcinoma: can it reduce neuropathy?. *Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer* 2009

Ruhstaller T, Popescu R, Bodis S, Schnider A, Terraciano L, Köberle D, Balmermajno S, Pestalozzi B, Borner M, von Moos R, Mingrone W, Hess V, Roth A, Schuller J, Widmer L, Swiss Group for Clinical Cancer Research (SAKK). Multicenter phase II trial of preoperative induction chemotherapy followed by chemoradiation with docetaxel and cisplatin for locally advanced esophageal carcinoma (SAKK 75/02). *Annals of oncology : official journal of the European Society for Medical Oncology / ESMO* 2009; 20:1522-8.

Ribi K, Pestalozzi B, Lombriser N, Borner M, von Moos R, Moosmann P, Hess V, Roth A, Honegger H, Schuller J, Köberle D, Ruhstaller T. Is a change in patient-reported dysphagia after induction chemotherapy in locally advanced esophageal cancer a predictive factor for pathological response to neoadjuvant chemoradiation?. *Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer* 2009; 17:1109-1116.

Ruhstaller T, Böhme C, Hess D, Hoefliger M, Mueller U, Köberle D, Spaeti B, Glaus A, Ribi K, Rufibach K, von Moos R, Thürlimann B. Breast cancer patients on endocrine therapy reveal more symptoms when self-reporting than in pivotal trials: an outcome research study. *Oncology* 2009; 76:142-8.

Baumann M, Weder P, Köberle D. Neue Behandlungsoptionen beim metastasierten Kolorektalkarzinom - Bewertung der aktuellen Studienresultate und Konsequenzen. *Schweizer Zeitschrift für Onkologie* 2009:14-19.

Templeton A, Marra G, Valtorta E, Heinimann K, Müller H, Köberle D, Gillessen Sommer S. Concordant colon tumors in monozygotic twins previously treated for prostate cancer. *Familial cancer* 2009; 8:167-71.

Renz M, Köberle D, Cerny T, Strasser F. Between utter despair and essential hope. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology* 2009; 27:146-9.

Köberle D, Rust C, Bieri G, Neuweiler J, Terraciano L, Ruhstaller T, Heitzmann F, Hess V, Winterhalder R, von Moos R, Burkhard R, Toepfer M. Phase II study of capecitabine and oxaliplatin given prior to and concurrently with preoperative pelvic radiotherapy in patients with locally advanced rectal cancer. *British journal of cancer* 2008; 98:1204-9.

Haug S, Anliker M, Köberle D. Dermatologische Nebenwirkungen der EGFR-Inhibitoren. *TMJ* 2008; 2008:7-11.

Köberle D, Peter I, Boggian K. Excruciating thigh pain and hepatic air collection. *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America* 2007; 45:1591-2, 1644-5.

Ruhstaller T, Thürlimann B, Köberle D, von Moos R. Is surgery still part of local therapy in patients with locally advanced esophageal carcinoma?. *JCO* 2007; 25:4025-6; author reply 4026-7.

Roth A, de Braud F, Seymour M, Widmer L, Glynn-Jones R, Leslie M, Wernli M, Maibach R, Rufibach K, Borner M, Köberle D, Saletti P, Bernhard J, Falk S, Stupp R, Fazio N, Swiss Group for Clinical Cancer Research. Docetaxel, cisplatin, and fluorouracil; docetaxel and cisplatin; and epirubicin, cisplatin, and fluorouracil as systemic treatment for advanced gastric carcinoma: a randomized phase II trial of the Swiss Group for Clinical Cancer Research. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology* 2007; 25:3217-23.

Klaeser B, Wiederkehr O, Köberle D, Mueller A, Bubeck B, Thürlimann B. Therapeutic impact of 2-[fluorine-18]fluoro-2-deoxy-D-glucose positron emission tomography in the pre- and postoperative staging of patients with clinically intermediate or high-risk breast cancer. *Ann Oncol* 2007; 18:1329-34.

Seeholzer N, Thürlimann B, Köberle D, Hess D, Korte W. Combining chemotherapy and low-molecular-weight heparin for the treatment of advanced breast cancer: results on clinical response, transforming growth factor-beta 1 and fibrin monomer in a phase II study. *Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis* 2007; 18:415-23.

Herrmann R, Stemmer S, Tamas K, Kornek G, Köberle D, Cina S, Bernhard J, Dietrich D, Scheithauer W, Swiss Group for Clinical Cancer Research, Mingrone W, Köhne C, Bodoky G, Ruhstaller T, Glimelius B, Bajetta E, Schüller J, Saletti P, Bauer J, Figer A, Pestalozzi B, Central European Cooperative Oncology Group. Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology* 2007; 25:2212-7.

Greuter S, Jörgen M, Köberle D. Adjuvante Therapie des Kolonkarzinoms. *Onkologie* 2007; 3:20-24.

Hess D, Ribi K, Ballabeni P, Schuller J, Rauch D, Rochlitz C, Mattmann S, Schonenberger A, Pagani O, Thürlimann B, Köberle D, Swiss Group for Clinical Cancer Research. Capecitabine and vinorelbine as first-line treatment in elderly patients (> or =65 years) with metastatic breast cancer. A phase II trial (SAKK 25/99). *Oncology* 2007; 73:228-37.

Perey L, Goldhirsch A, Köberle D, Clément P, Dietrich D, Fiche M, Wildiers H, Nolé F, Zaman K, Hawle H, Paridaens R, Thürlimann B. Clinical benefit of fulvestrant in postmenopausal women with advanced breast cancer and primary or acquired resistance to aromatase inhibitors: final results of phase II Swiss Group for Clinical Cancer Research Trial (SAKK 21/00). *Ann Oncol* 2007; 18:64-9.

Köberle D, Thürlimann B. Letrozole as upfront endocrine therapy for postmenopausal women with hormone-sensitive breast cancer: BIG 1-98. *Breast Cancer Res Treat* 2007; 105 Suppl 1:55-66.

Thürlimann B, Köberle D, Senn H. Guidelines for the adjuvant treatment of postmenopausal women with endocrine-responsive breast cancer: past, present and future recommendations. *EJC* 2007; 43:46-52.

Köberle D, Thürlimann B. Letrozole as adjuvant endocrine therapy in postmenopausal women with breast cancer. Expert review of anticancer therapy 2006; 6:5-10.

Köberle D, Thürlimann B. Adjuvant endocrine therapy in postmenopausal breast cancer patients. Breast (Edinburgh, Scotland) 2005; 14:446-51.

Jörger M, Köberle D, Neumann H, Gillessen Sommer S. Von Hippel-Lindau disease--a rare disease important to recognize. Onkologie 2005; 28:159-63.

Borner M, Roth A, Lanz D, Brauchli P, Honegger H, Köberle D, Herrmann R, Rauch D, Saletti P, Wernli M, Popescu R, Dietrich D, Bernhard J, Swiss Group for Clinical Cancer Research (SAKK), Berne, Switzerland. A randomized phase II trial of capecitabine and two different schedules of irinotecan in first-line treatment of metastatic colorectal cancer: efficacy, quality-of-life and toxicity. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2005; 16:282-8.

Thürlimann B, Rochlitz C, Aebi S, Perey L, Pagani O, Ballabeni P, Senn I, Köberle D, Hess D, Goldhirsch A. Anastrozole ('Arimidex') versus tamoxifen as first-line therapy in postmenopausal women with advanced breast cancer: results of the double-blind cross-over SAKK trial 21/95--a sub-study of the TARGET (Tamoxifen or 'Arimidex' Randomized Group Efficacy and Tolerability) trial. Breast Cancer Res Treat 2004; 85:247-54.

Köberle D, Perey L, Thürlimann B, Swiss Group for Clinical Cancer Research (SAKK). Re: Playing the old piano: another tune for endocrine therapy. Journal of the National Cancer Institute 2004; 96:555-6; author reply 556-7.

Köberle D, Thürlimann B. Anastrozole: pharmacological and clinical profile in postmenopausal women with breast cancer. Expert review of anticancer therapy 2001; 1:169-76.

Gessner U, Köberle D, Thürlimann B, Bacchus L, Horisberger B. Economic analysis of terminal care for patients with malignant osteolytic bone disease and pain treated with pamidronate. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 2000; 8:115-22.

Köberle D, Henz S, Flury D, Mayer R. [Yellow nail syndrome]. Schweizerische medizinische Wochenschrift 1999; 129:1342.

Köberle D, Bacchus L, Thürlimann B, Senn H. Pamidronate treatment in patients with malignant osteolytic bone disease and pain: a prospective randomized double-blind trial. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 1999; 7:21-7.

Engler H, Köberle D, Thürlimann B, Senn H, Riesen W. Diagnostic and prognostic value of biochemical markers in malignant bone disease: a prospective study on the effect of bisphosphonate on pain intensity and progression of malignant bone disease. Clinical chemistry and laboratory medicine : CCLM / FESCC 1998; 36:879-85.

Projekte (12)

Integration of Cetuximab, in combination with local radiotherapy, in perioperative chemotherapy of resectable and locally advanced gastric cancer. A pilot phase I B-trial

Klinische Forschung - 17.04.2012 - 31.03.2013

Abgebrochen

Long Term Follow-up of BIG 1-98: An observational study in centers that participated in the 4-arm option of the BIG 1-98 trial

Klinische Forschung - 20.04.2011 - 31.12.2015

Automatisch geschlossen

International, multicenter, open-label, phase II study to investigate the efficacy and safety of multiple doses of IMAB362 in patients with advanced adenocarcinoma of the stomach or the lower esophagus

Klinische Forschung - 26.01.2011 - 30.06.2012

Abgeschlossen

Entwicklung von Dienstleistungsmodellen der integrierten Onkologie und Palliative Care: Untersuchung von temporalen Aspekten, Involvierung von Onkologen, und Chemotherapie-Gebrauch

Klinische Forschung - 10.11.2010 - 31.10.2011

Abgeschlossen

Capecitabine and Oxaliplatin prior and concurrent to preoperative pelvic radiotherapy in patients with locally advanced rectal cancer. A survival analysis

Klinische Forschung - 25.06.2010 - 31.03.2011

Automatisch geschlossen

Multimodal therapy with and without cetuximab in patients with locally advanced esophageal carcinoma. An open-label phase III trial

Klinische Forschung - 17.05.2010 - 31.01.2013

Automatisch geschlossen

Sorafenib alone or in combination with everolimus in patients with unresectable hepatocellular carcinoma. A randomized multicenter phase II trial

Klinische Forschung - 26.10.2009 - 31.10.2011

Automatisch geschlossen

FLOxTox: Assessment of the Polygenic Basis of Adverse Reactions to 5-Fluorouracil/Leucovorin/Oxaliplatin of Colorectal Cancer Patients Using a Pathway Approach

Klinische Forschung - 31.08.2009 - 31.08.2011

Abgeschlossen

Neoadjuvant radiotherapy combined with capecitabine and sorafenib in patients with advanced, K-ras mutated rectal cancer. A multicenter phase I/IIa trial

Klinische Forschung - 18.03.2009 - 30.10.2011

Automatisch geschlossen

Neoadjuvant radiotherapy and capecitabine with or without panitumumab in patients with advanced, K-ras unmutated rectal cancer: A randomized multicenter phase II trial

Klinische Forschung - 16.02.2009 - 01.07.2011

Automatisch geschlossen

Smiley-Projekt: Prädiktive Faktoren einer guten Entscheidungsfindung für eine Palliativtherapie bei Patienten im Onkologie-Netzwerk KSSG

Klinische Forschung - 05.01.2009 - 30.01.2011

Automatisch geschlossen

Trastuzumab monotherapy followed by the combination of trastuzumab and letrozole in post-menopausal women with ER-positive, HER-2 positive advanced breast cancer resistant to a nonsteroidal aromatase inhibitor

Klinische Forschung - 01.01.2005 - 30.03.2011

Automatisch geschlossen